nach oben

Journal of Neuro-Oncology

Erschienen in:

01.01.2015 | Laboratory Investigation

The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome

verfasst von: Lei Zhang, Yong Yan, Ying Jiang, Yong Cui, Yongxiang Zou, Jun Qian, Chun Luo, Yicheng Lu, Xiaojun Wu

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The spalt-like transcription factor 4 (SALL4) gene has been demonstrated to be overexpressed in many malignancies, but little is known about its expression in gliomas. To explore the expression of SALL4 in patients with gliomas and the relationship between SALL4 expression and clinicopathologic characteristics, qPCR and immunohistochemical staining were used to investigate the SALL4 expression level in 54 glioma specimens and seven normal brain tissues. In vitro, siRNAs against SALL4 in U251 cell line were constructed and cell proliferation was evaluated by CCK8 assay. The SALL4 expression level in glioma was significantly higher than that in normal brain tissues (P < 0.05). Both qPCR and immunohistochemical analysis found that the expression of SALL4 was tightly correlated with glioma pathology grade (P < 0.05). Analysis using glioma and normal brain tissues revealed that SALL4 was positively proportionated to glioma cell differentiation with high sensitivity (92.59 %) and specificity (85.71 %). Survival analysis indicated the SALL4 expression was an independent prognostic factor. High level of SALL4 expression was correlated with poor outcome in patients with gliomas. This result agreed with the negative correlation between SALL4 expression and overall survival period obtaining in GBM patients from the cancer genome atlas database. The CCK8 experiments demonstrated SALL4 could significantly inhibit cell proliferation in U251 cell line (P < 0.05). The findings of the current study indicated that the SALL4 may play an important role in progression, development and maintenance of glioma.

Nur mit Berechtigung zugänglich

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A, Scheithauer B, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRef

Van Meir E, Hadjipanayis C, Norden A, Shu H, Wen P, Olson J (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60:166–193PubMedCentralPubMedCrossRef

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R, Ludwin S, Allgeier A, Fisher B, Belanger K, Hau P, Brandes A, Gijtenbeek J, Marosi C, Vecht C, Mokhtari K, Wesseling P, Villa S, E E, G T, W M, L D, JG C, RO M, EOfRaToCBTaRO Groups, Group. NCIoCCT (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC–NCIC trial. Lancet Oncol 10:459–466PubMedCrossRef

Mohyeldin A, Chiocca E (2012) Gene and viral therapy for glioblastoma: a review of clinical trials and future directions. Cancer J 18:82–88PubMedCrossRef

Nicholas M, Lukas R, Jafri N, Faoro L, Salgia R (2006) Epidermal growth factor receptor—mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12:7261–7270PubMedCrossRef

Hägerstrand D, He X, Bradic Lindh M, Hoefs S, Hesselager G, Ostman A, Nistér M (2011) Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro Oncol 13:1178–1191PubMedCentralPubMedCrossRef

Kohlhase J, Schuh R, Dowe G, Kühnlein R, Jäckle H, Schroeder B, Schulz-Schaeffer W, Kretzschmar H, Köhler A, Müller U, Raab-Vetter M, Burkhardt E, Engel W, Stick R (1996) Isolation, characterization, and organ-specific expression of two novel human zinc finger genes related to the drosophila gene spalt. Genomics 38:291–298PubMedCrossRef

Zhang J, Tam W, Tong G, Wu Q, Chan H, Soh B, Lou Y, Yang J, Ma Y, Chai L, Ng H, Lufkin T, Robson P, Lim B (2006) Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol 8:1114–1123PubMedCrossRef

Yang J, Gao C, Chai L, Ma Y (2010) A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PLoS One 5:e10766PubMedCentralPubMedCrossRef

10.

Cao D, Humphrey P, Allan R (2009) SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. Cancer J 115:2640–2651CrossRef

11.

Cao D, Li J, Guo C, Allan R, Humphrey P (2009) SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol 33:1065–1077PubMedCrossRef

12.

Liu A, Cheng L, Du J, Peng Y, Allan R, Wei L, Li J, Cao D (2010) Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol 34:697–706PubMed

13.

Wang F, Liu A, Peng Y, Rakheja D, Wei L, Xue D, Allan R, Molberg K, Li J, Cao D (2009) Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placentallike alkaline phosphatase, alpha-fetoprotein, and glypican-3. Am J Surg Pathol 33:1529–1539PubMedCrossRef

14.

Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck A, Yamazaki Y, Wauthier E, Tajiri H, Miller L, Wang X, Reid L, Nakauchi H (2013) Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 57:1469–1483PubMedCrossRef

15.

Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N (2011) Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep 26:965–970PubMed

16.

Kobayashi D, Kuribayshi K, Tanaka M, Watanabe N (2011) SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. Int J Oncol 38:933–939PubMed

17.

Yong K, Gao C, Lim J, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong C, Wong K, Lee S, Ravikumar S, Srivastava S, Tian X, Poon R, Fan S, Luk J, Dan Y, Salto-Tellez M, Chai L, Tenen D (2013) Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 13:2266–2276CrossRef

18.

Aguila J, Liao W, Yang J, Avila C, Hagag N, Senzel L, Ma Y (2011) SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. Blood 118:576–585PubMedCentralPubMedCrossRef

19.

Yang J, Aguila J, Alipio Z, Lai R, Fink L, Ma Y (2011) Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4. J Hematol Oncol 4:38PubMedCentralPubMedCrossRef

20.

Rao S, Zhen S, Roumiantsev S, McDonald L, Yuan G, Orkin S (2010) Differential roles of Sall4 isoforms in embryonic stem cell pluripotency. Mol Cell Biol 30:5364–5380PubMedCentralPubMedCrossRef

21.

Yang J, Chai L, Fowles T, Alipio Z, Xu D, Fink L, Ward D, Ma Y (2008) Genome–wide analysis reveals Sall4 to be a major regulator of pluripotency in murine–embryonic stem cells. Proc Natl Acad Sci U S A 105:19756–19761PubMedCentralPubMedCrossRef

22.

Yang J, Chai L, Fowles T, Alipio Z, Xu D, Fink L, Ward D, Ma Y (2008) Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells. Proc Natl Acad Sci U S A 105:19756–19761PubMedCentralPubMedCrossRef

23.

Lim C, Tam W, Zhang J, Ang H, Jia H, Lipovich L, Ng H, Wei Sung W, Robson P, Yang H, Lim B (2008) Sall4 regulates distinct transcription circuitries in different blastocyst-derived stem cell lineages. Cell Stem Cell 3:543–554PubMedCrossRef

24.

Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, Zhang Y, Ling E, Gao J, Hao A (2011) Expression of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 59:763–775PubMedCrossRef

25.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872PubMedCrossRef

26.

Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y, Cao X, Ling E, Hao A (2009) Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia 57:724–733PubMedCrossRef

27.

Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D (2011) SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics 8:139–147PubMed

28.

Forghanifard M, Moghbeli M, Raeisossadati R, Tavassoli A, Mallak A, Boroumand-Noughabi S, Abbaszadegan M (2013) Role of SALL4 in the progression and metastasis of colorectal cancer. J Biomed Sci 20:6PubMedCentralPubMedCrossRef

29.

He J, Zhang W, Zhou Q, Zhao T, Song Y, Chai L, Li Y (2013) Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol 45:1962–1973PubMedCrossRef

30.

Wang F, Guo Y, Chen Q, Yang Z, Ning N, Zhang Y, Xu Y, Xu X, Tong C, Chai L, Cui W (2013) Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. J Hematol Oncol 6:73PubMedCentralPubMedCrossRef

Titel: The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome
verfasst von: Lei Zhang
Yong Yan
Ying Jiang
Yong Cui
Yongxiang Zou
Jun Qian
Chun Luo
Yicheng Lu
Xiaojun Wu
Publikationsdatum: 01.01.2015
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1646-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab

Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2

Post progression survival in glioblastoma: where are we?

Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab